Study Links Cannabis Use to Increased Risk of Type 2 Diabetes
A recent study suggests that adults who use cannabis may be almost four times more likely to develop type 2 diabetes compared to those who do not use it. Conducted by Dr. Ibrahim Kamel and his team at Boston Medical Center, the research examined medical records from 54 healthcare organizations in the U.S. and Europe.
The study analyzed data from approximately 96,800 people with cannabis-related diagnoses, ranging from casual users to those with dependency issues. This group was compared to over 4.16 million individuals who had no history of drug use or chronic health conditions.
Over five years, it was found that 2.2% of cannabis users developed type 2 diabetes, contrasted with just 0.6% among non-users. Even after accounting for other health concerns—such as high blood pressure, cholesterol, heart disease, and alcohol or cocaine use—those who used marijuana still had a heightened risk of diabetes.
Experts believe that cannabis might influence appetite and metabolism, potentially leading to poor eating habits that result in elevated blood sugar levels over time. With the growing acceptance and legalization of marijuana, many view it as a safer alternative to substances like alcohol or tobacco. However, this research highlights that its long-term health risks may be more significant than previously believed.
Dr. Kamel emphasized the importance of understanding these health risks as cannabis use becomes more widespread. He suggested that healthcare providers should engage with patients about their cannabis use to monitor potential metabolic health concerns.
While the findings are concerning, the researchers did acknowledge some limitations. The study relied on retrospective data, which means it looked back at existing patient records rather than tracking new cases over time. This makes it challenging to definitively conclude that cannabis use directly causes diabetes.
Additionally, the risk may vary depending on frequency of use; occasional users might not face the same risks as frequent consumers. There is also the potential for bias in self-reported usage, particularly in areas where cannabis remains illegal.
Moving forward, doctors may need to routinely discuss cannabis consumption with their patients to assess overall diabetes risk and consider the necessity of metabolic monitoring. This research underscores the importance of integrating awareness of diabetes risks into treatment and counseling for substance use disorders.
